Professorships of 2024

"Proteins are converted in the cell in a natural way," says Prof. Nowak, who wants to use such recycling processes to discover new drugs. Proteins are broken down by the so-called ubiquitin-proteasome system. Special enzymes, known as E3 ligases, bind misfolded and dysfunctional proteins and mark them with ubiquitin for destruction by the proteasome - a cellular waste disposal system where the proteins are chopped into pieces and recycled. Proteolytic chimeras (PROTACs), or molecular glue degraders, can disrupt this natural degradation process and target proteins that were previously considered non-therapeutic. The dumbbell-shaped PROTACs glue the target protein to the E3 ubiquitin ligase via their two binding arms, thus enabling the transfer of ubiquitins and subsequent degradation by the proteasome. "We call this targeted protein degradation. This is because we can now develop PROTACs or find molecular glue degraders with which we can specifically attack proteins that were previously difficult to combat," says Prof. Nowak.

His dream is to contribute to the discovery of new drugs
Together with his team, he wants to find out how protein interactions within a cell can be redesigned for therapeutic benefit in this way. "The feeling that we have discovered something new is exciting. In current research, the discovery is a team effort and that's what makes it so special," says Prof. Nowak. For this reason, he would like to create a long-term network at the UKB and the University of Bonn that focuses on various aspects of drug discovery. It will involve clinicians, basic researchers and the biotechnology sector in order to organize research and lead it towards therapeutic development. "Being embedded in a hospital at UKB, I find it particularly important to focus on research that has translational potential. Drug discovery is a challenging and sometimes lengthy process, but it always starts with a fundamental discovery and often with a chemical or biological tool. In my lab, which focuses on targeted protein degradation and small molecule-induced proximity, I want to develop these novel technologies, discover new mechanisms of action of small molecules and further develop them for therapeutic potential," says Prof. Nowak.

The biochemist was happy to come to Bonn because the UKB and the University of Bonn have put together a number of outstanding research groups with a strong focus on immunology. "The combination of immunology with cutting-edge technologies such as chemistry, proteomics, nanobodies, structural biology or gene editing fits perfectly with my expertise in targeted protein degradation, induced proximity and the discovery of small molecules for drugs," says the father of three, who travels and does sports - skiing or cycling - in his spare time. He would love to return to gliding - one of his hobbies from his university days.